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ABSTRACT 
 
Background: Several patients with chronic kidney disease (CKD) undergoing routine 
hemodialysis (HD) have abnormalities of left ventricle (LV) morphology with feature LV 
dilation due to volume overload and chronic ischemia, which has high risk of mayor adverse 
cardiovascular event. Anemia causes LV dilation through high output state mechanism. 
Anemia management in CKD patients causes hemoglobin (Hb) fluctuations or hemoglobin 
variability (Hb-Var) which is thought to cause LV dilation through relative repetitive ischemia 
mechanisms. Research linking Hb-Var as risk factor for LV dilation has never been done. 
Method: Matched case-control study was carried out by taking echocardiographic data of 
CKD patients undergoing routine HD in HD Unit Dr. Sardjito hospital. The LV diameter is 
divided into samples with LV (+) dilated profile as a case group, and LV (-) dilated as a 
control group. Matching was done on variables of age, gender and HD frequency. The Hb-
Var parameter was calculated by the residual SD method based on the Hb value in the last 6 
months. Fisher-Exact hypothesis test was used to assess the relationship between Hb-Var 
and LV dilation, while the logistic regression test was used for multivariate testing. 
Result: Total of 79 subjects entered in this study, there were 23 subjects of case groups 
and 28 subjects of control group after matching and adjusting the control formula. The 
proportion of high Hb-Var in the group with dilated LV (+) and dilated LV (-) were 21.7% and 
17.9%, respectively. The Fisher-Exact test shows that there is no relationship between Hb-
Var and LV dilation, with OR 1.28 (95% CI 0.32-5.10). Logistic regression test shows that 
there are no variables that affect independently of LV dilation. 
Summary: CKD patients undergoing routine HD with high Hb-Var profiles do not have a 
higher risk of LV dilation than patients with low Hb-Var profiles. 
 
Keywords: hemoglobin variability; left ventricle dilation; chronic kidney disease, 
hemodialysis 
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INTISARI 
 
Latar Belakang: Sebagian pasien penyakit ginjal kronik (PGK) yang menjalani 
hemodialisis (HD) rutin memiliki abnormalitas morfologi ventrikel kiri (VKi) berupa dilatasi 
VKi oleh karena volume overload dan iskemia kronik, yang memiliki risiko tinggi kejadian 
kardiovaskular mayor. Anemia menyebabkan dilatasi VKi melalui mekanisme high output 
state. Manajemen anemia pada pasien PGK menyebabkan fluktuasi hemoglobin (Hb) atau 
variablitas hemoglobin (Var-Hb) yang diduga menyebabkan dilatasi VKi melalui mekanisme 
iskemia repetitif relatif. Penelitian yang menghubungkan Var-Hb sebagai faktor risiko dilatasi 
VKi belum pernah dilakukan. 
Metode Penelitian: Studi matched kasus-kontrol dilakukan dengan mengambil data 
ekokardiografi pasien PGK yang menjalani HD rutin di Unit HD RSUP Dr. Sardjito. Diameter 
VKi dibagi menjadi sampel dengan profil dilatasi VKi (+) sebagai kelompok kasus, dan 
dilatasi VKi (-) sebagai kelompok kontrol. Matching dilakukan pada variabel usia, jenis 
kelamin dan frekuensi HD. Parameter Var-Hb dihitung dengan metode residual SD 
berdasarkan nilai Hb dalam 6 bulan terakhir. Uji hipotesis Fisher-Exact dipakai untuk menilai 
hubungan antara Var-Hb dan dilatasi VKi, sedangkan uji regresi logistik dipakai untuk uji 
multivariat. 
Hasil: Sebanyak 79 subjek yang masuk dalam penelitian ini, terdapat 23 subjek kelompok 
kasus dan 28 subjek kelompok kontrol setelah proses matching dan penyesuaian rumus 
kontrol. Proporsi Var-Hb tinggi pada kelompok dengan dilatasi VKi (+) dan dilatasi VKi (-) 
masing-masing 21,7% dan 17,9%. Uji Fisher-Exact menunjukkan tidak terdapat hubungan 
antara Var-Hb dengan dilatasi VKi, dengan OR 1,28 (IK 95% 0,32-5,10). Uji regresi logistik 
menunjukkan tidak terdapat variabel yang mempengaruhi secara independen terhadap 
dilatasi VKi. 
Simpulan: Pasien PGK yang menjalani HD rutin dengan profil Var-Hb tinggi tidak memiliki 
risiko lebih tinggi untuk terjadi dilatasi VKi dibandingkan pasien dengan profil Var-Hb rendah. 
 
INTRODUCTION 
Patients with chronic kidney 
disease (CKD) who have undergone 
chronic hemodialysis (HD) have cardiac 
structural abnormalities in the form of 
asymmetric hypertrophy, eccentric 
remodeling and geometric distortion.1 Left 
ventricular (LV) morphology changes in 
CKD patients undergoing routine HD are 
thought to be the cause of more than 80 % 
of this population die from cardiovascular 
causes, namely arrhythmia or sudden 
cardiac death (SCD).2 Correction of 
traditional and non-traditional risk factors 
is crucial because cardiorenal syndrome 
(CRS) type IV includes chronic 
cardiovascular processes in CKD.3,4 
Anemia is the most common 
complication in CKD, in addition to non-
traditional risk factors, which have an 
adverse effect on quality of life, and 
increase morbidity and mortality.3,5 
Anemia causes high output state 
conditions characterized by increased 
venous return, arterial vasodilation and 
increased sympathetic activity, causing 
volume overload. Volume overload status 
will cause myocardial remodeling in the 
form of addition of heart muscle mass in 
series or eccentric hypertrophy, which is 
characterized by LV dilation and left 
ventricular hypertrophy (LVH).3 
Full range of therapeutic modalities 
used in anemia management is not always 
beneficial, because too high Hb values 
have been known to cause poor 
cardiovascular consequences.6 National 
Kidney Foundation Dialysis Outcome 
Quality Initiative (NKF-DOQI) suggests 
that hemoglobin levels should be 
maintained between 11- 12 g / dl in CKD 
patients.7  
In fact, it is not easy to maintain Hb 
levels in a narrow range, so that Hb levels 
show fluctuating values based on 
laboratory measurements every month in 
CKD patients, which is called hemoglobin 
variability (Hb-Var). Changing Hb levels 
are expected to accelerate LV remodeling 
process more rapidly.8 Relative ischemia 
and recurrent hypoxia due to conditions of 
anemia in CKD cause signal activation of 
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myocardial cell growth, which has an 
impact on LV hypertrophy and dilation.9 
One specific parameter to assess 
the effect of Hb-Var is the LV diameter. 
The ability of LV diameter as a component 
of SCD risk stratification can help in the 
management of primary prevention of 
SCD.10 Most common causes of LV 
dilation are ischemic heart disease, other 
etiologies include severe organic heart 
valve disease, congenital heart disease, 
cardiomyopathy, and chronic 
hypertension.11,12 Based on above theory, 
Hb-Var which has an ischemic effect on 
the myocardium has a LV dilatation effect 
in CKD patients. Research linking Hb-Var 
to CKD patients undergoing routine HD 
with LV dilated has never been done. 
 
METHODS 
This study is an analytic 
observational using paired case-control 
design to looking for the LV dilation risk 
factors in CKD patients undergoing routine 
HD. The case group in this study were 
patients with LVdilated (+) profile, and as 
a control group were patients with LV 
dilated (-) profiles.  
Matching characteristics between 
case and control groups included a 
combination of age variables (paired with 
subject groups within 5 years), gender 
(men with men, women and women), and 
HD frequency (2 times/week). The study 
was conducted in HD room and 
Echocardiography room of the Dr. General 
Hospital Sardjito Yogyakarta from 
December 2017 to April 2018. Inclusion 
criteria consist of stage 5 CKD patients 
undergoing routine HD, willing to be a 
research subject and signed an informed 
consent, there is a serial Hb examination 
every month in the last 6 months. 
Exclusion criteria consist of 
echocardiographic features that are 
difficult to assess, history of 
atherosclerotic ischemic heart disease, 
history of congenital heart disease, history 
of severe organic heart valve disease, 
history of cardiomyopathy heart disease, 
history of primary erythrocyte formation 
disorders, and a history of malignancy. 
Research subjects were collected 
by looking data registers in the HD room. 
When the subject underwent routine HD at 
HD Unit of Dr. SardjitoHospital, the subject 
was asked about his willingness to 
participate in this study by signing an 
informed consent. After agreement, the 
patient's data is then tracked to see the 
basic characteristics, comorbidities, 
laboratory results, and therapeutic history 
through medical records and interviews.  
Laboratory data include Hb levels, 
blood urea nitrogen (BUN), creatinine, 
albumin, and iron status. Laboratory blood 
sampling is carried out every month after 
the HD procedure, in accordance with the 
routine procedure at HD unit Sardjito 
hospital. Hb value is taken from laboratory 
examination in the past 6 months.  
The six Hb values are 
calculatedbased on formula : 
Hb-
Var
√
( ̅   ) ( ̅   ) ( ̅   ) ( ̅   ) ( ̅   ) ( ̅   )
 
, 
 
where  ̅ is the Hb mean in the last 6 
months, and    is the Hb level in the 
month-i, then the result are classified into 
the high Hb-Var group (≥1 g/dl) or low (<1 
g/dl). 
Echocardiographic data was taken 
at the Echocardiography examination 
room of the Sardjito hospital. 
Transthoracal echocardiography (TTE) is 
performed after an HD procedure in less 
than 24 hours post HD procedure. All 
patients underwent TTE examination with 
a VIVID 7 device (General Electric, USA). 
Left ventricle diameter measurement uses 
M-mode method by placing the cursor 
perpendicular to the mitral tip, calculated 
from anterior basal border to posterior 
basal border of endocardium. Calculation 
of LV diameter is performed 
intraobserverly and interobservered by 2 
expert examiners, offline from a 
workstation computer using Echopac 
(General Electric) software which is blind 
to clinical datasubject. Left vetricle 
diameter values that have been validated 
are classified into groups with LV dilated 
profiles and non-LV dilated based on 
American Society Cardiology criteria. 
Collecting data were analyzed 
statistically with IBM SPSS Statistics 23 
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program. Basic characteristics data are  
presented based on matching results from 
variables that can be controlled through 
the t-test. Other variables that are 
examined included in the basic 
characteristics data, carried out a 
comparative test with t-test and normality 
test with Kolmogorov-Smirnov. 
Hemoglobin variability hypothesis 
testing as a risk factor for LV dilation is 
performed using a 2x2 table with Chi-
square analysis if the expected <5 is a 
maximum of 20% of the cell count, or 
Fisher's Exact if the Chi-square condition 
is not met. Bivariate analysis was 
conducted to determine the strength of the 
confounding variable relationship with LV 
dilation. P values  <0.25 indicate that 
these variables are eligible to be included 
in multivariate analysis. Multivariate 
analysis was performed to determine 
independent risk factors associated with 
LV dilation. The results of this analysis are 
reported as an OR with a value of p <0.05 
indicating that the variable is a risk factor 
of LV dilation. 
 
RESULTS 
This research was conducted by 
taking an affordable population of CKD 
patients undergoing routine HD in HD Unit 
of Dr. Sardjito hospital. One hundred 
twenty eight patients who had routine HD 
schedules were given information to 
participate as subjects in this study.  
After exclusion, there were 79 
subjects left which would then be divided 
into case groups and controls based on 
whether or not LV was dilated. A total of 
51 subjects consisting of 23 case subjects 
and 28 control subjects (figure 1).
 
 
 
 
Figure 1. Subject selection scheme with matching method 
 
 
Subjects who met the inclusion and 
exclusion criteria (n = 79) 
LV dilation classification 
LV dilation (+) 
n = 28 
LV dilation (-) 
n = 51 
Matching to aged, sex, dan HD duration 
23 paired-matchingcase-control 
(less than sample minimal) 
Adjusted control so that the conditions of the case-control  
are met, adding 5 control 
Total samples (n = 51) 
cases (n = 23), controls (n = 28) 
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Most CKD patients who underwent 
routine HD showed a history of 
hypertension, with one third of the total 
population having comorbid diabetes 
mellitus. Anemic status of this population 
shows that Hb levels are always below 
normal values with mean Hb levels in the 
last 6 months and maximum Hb in case 
and control groups are 9.2/10.3 g/dl and 
9.2/10.9 g/dl, respectively. Median Hb-Var 
in the case and control groups showed 
values of 0.77 g/dl and 0.78 g/dl, with high 
Hb-Var values ranging from 15-20%. 
Profile of LV geometry in the LV dilation 
(+) group showed concentric hypertrophy 
of 73.9% and eccentric hypertrophy of 
26.1%, while the LV dilation (-) group 
showed 39.3% normal geometry, 50% 
concentric hypertrophy, and 10.7% 
eccentric hypertrophy. Most CKD patients 
undergoing routine HD use angiotensin 
converting enzyme inhibitors (ACE-I) or 
angiotensin receptor blockers (ARB), and 
calcium channel blockers (CCB), with only 
a few using β-blockers (table 1). 
 
Table1. Baseline characteristics of CKD patients undergoing routine HD based on  
LV dilation (+) and LV dilation (-) classification 
 
Characteristics 
LV dilation (+)  
(n = 23 / 45%) 
LV dilation (-) 
(n = 28 / 55%) 
p value 
Sex, men (%) 
Age (mean ± SD) 
HD frequency, times/week (mean±SD) 
Body surface area, m2 (mean±SD) 
HD duration, month (median; IQR) 
Hypertension (%) 
Diabetes mellitus (%) 
Laboratoryparameters 
BUN, mg/dl (median; IQR) 
Creatinine, mg/dl (mean±SD) 
Albumin, g/dl (median; IQR) 
Hemoglobin (last 6 month) 
Mean, g/dl (mean ± SD) 
Minimum, g/dl (mean ± SD) 
Maximum, g/dl (mean ± SD) 
Hb-Var, g/dl (median; IQR) 
Hb-Var, high (%) 
Hematocrit, % (mean ± SD) 
TTE parameters 
LVIDd, mm (median; IQR) 
   Men, mm (mean ± SD) 
   Women, mm (mean ± SD) 
LVEF (mean ± SD) 
LV geometry 
   Normal (%) 
   Concentric hypertrophy (%) 
   Eccentric hypertrophy (%) 
Drugs 
ACE-I or ARB (%) 
CCB (%) 
β-blocker (%) 
13 (56.5) 
50.0±14.4 
2.0±0.0 
1.58±0.18 
48; 60 
22 (95.7) 
8 (34.8) 
 
57.0; 19.7 
10.6±27.2 
4.0 ; 0.6 
 
9.2±1.0 
8.3±1.4 
10.3±1.3 
0.77; 0.53 
5 (21.7) 
27.5±4.0 
 
54.0; 6.0 
55.0; 6.0 
51.5; 4.0 
56.0±15.0 
 
0 
17 (73.9) 
6 (26.1) 
 
22 (95.7) 
19 (82.6) 
3 (13.0) 
16 (57.1) 
51.5±13.4 
2.0±0.0 
1.60±0.21 
36; 81 
24 (85.7) 
10 (35.7) 
 
53.2; 23.1 
9.7±8.3 
3.9 ; 0.4 
 
9.2±1.4 
8.9±1.6 
10.9±1.5 
0.78; 0.32 
5 (17.9) 
28.2±3.8 
 
46.0; 5.0 
47.5; 4.0 
44.5; 4.0 
69.0±10.0 
 
11 (39.3) 
14 (50.0) 
3 (10.7) 
 
20 (71.4) 
20 (71.4) 
1 (3.6) 
0.97* 
0.72* 
1.00* 
0.61 
0.66 
0.24 
0.95 
 
0.34 
0.41 
0.46 
 
0.13 
0.21 
0.12 
0.17 
0.73 
0.15 
 
<0.001 
 
 
<0.001 
0.002 
 
 
 
 
0.03 
0.35 
0.22 
*) Matching variable. 
EF: ejection fraction; IQR: interquartile range; LVIDd: left ventricle internal diameter at 
diastole; SD: standard deviation 
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Table 2. Hypothesis test Hb-Varas risk factor for LV dilation 
 
 LV dilation (+) LV dilation (-) Total OR (95%CI) 
High Hb-Var 5 (21.7%) 5 (17.9%) 10 
1.28 (0.32-5.10) 
p=0.50 
Low Hb-Var 18 (78.3%) 23 (82.1%) 41 
Total 23 28 51 
 
 
 
Table 3. Multivariateanalysis of risk factors for LV dilation 
 
Variables OR (95% CI) p 
Hb-Var 
Body surface area 
HD duration 
Hypertension 
Diabeter mellitus 
Albumin 
Hb mean 
ACE-I / ARB 
CCB 
β-blocker 
0.86 (0.17-4.33) 
0.17 (0.01-8.16) 
1.00 (0.98-1.01) 
<0.01 (<0.01) 
0.5 (0.12-2.14) 
1.39 (0.38-5.00) 
0.94 (0.46-1.92) 
<0.01 (<0.01) 
0.51 (0.06-4.37) 
5.10 (0.38-68.09) 
0.86 
0.37 
0.94 
0.99 
0.35 
0.62 
0.86 
0.99 
0.54 
0.22 
 
This study uses a case-control 
design, so Chi-square analysis is used 
with the calculation of OR. Fisher-Exact 
test showed p=0.5, so it was concluded 
that Hb-Var was not a risk factor for LV 
dilation both clinically and statistically, in 
CKD patients undergoing routine HD with 
OR 1.28 (0.32-5.10) (table 2). Multivariate 
test with logistic regression showed that all 
variables suspected of risk factors did not 
significantly influence LV dilation (table 3). 
 
DISCUSSION 
This study using a case-control 
design to assess effect of Hb-Var cause  
LV dilation in CKD patients, especially 
those undergoing routine HD. The 
advantage of the case-control method is 
that the characteristics of the subjects in 
both case and control populations can be 
equated so that the expected output 
proportion is the same, and is very useful 
in the population of CKD patients 
undergoing routine HD with many 
comorbidities and risk factors that 
influence LV dilation. The second 
advantage is the case-control design is 
suitable to detect rare cases or risk 
factors, which in this study is Hb-Var 
which has a complex pathophysiology and 
dominance of the influence of other risk 
factors.  
The third advantage is the 
statistical output of case-control designs in 
the form of OR that have better statistical 
and clinical value than the risk of 
prevalence in cross-sectional designs, 
even though they are inferior to relative 
risk (RR). The method of selecting 
samples with matching in this study is 
conducted on variables that can be 
controlled, namely HD frequency, age and 
sex with an acceptable limit of agreement 
of 0.672, so that the matching is expected 
to be appropriate. 
More than 90% patients in this 
study had comorbid hypertension. 
Hypertension is the most common 
complication in CKD, and its prevalence 
increases with increasing age and severity 
of disease.13 Thirty five percents patients 
in this study subject had a diabetes 
mellitus (DM) profile. The prevalence of 
the most common causes of CKD is DM, 
hypertension nephopathy, glomerulo 
nephritis, and other causes such as 
stones, nephrotic syndrome.14 Diabetes 
mellitus is a traditional risk factor for CKD 
that has a role in CKD progression 
through a mechanism of deteriorating 
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kidney function and influencing traditional 
risk factors and another non-traditional.15 
The anemia profile in this study 
showed mean 9.2 g/dl and maximum 10.7 
g/dl in the last 6 months, indicating an 
complication of CKD in the form of anemia 
which has not yet received optimal 
management so that the Hb value is 
maintained at the level of 11-12 g/dl as 
recommended NKF-DOQI. Management 
of anemia in CKD patients, especially 
those undergoing routine HD based on the 
consensus of the Indonesian Nephrology 
Association, requires correction of the 
overall cause of anemia before starting 
erythropoietin stimulating agent (ESA) 
therapy.16 Some condition to be 
considered related to correction of anemia 
include infection, iron status, and 
malnutrition. The risk of ESA hypo 
response will increase if these factors are 
not corrected.17–19 
Mean Hb-Var obtained value 0.7 
g/dl with a high category 19.8%. 
Hemoglobin variability is associated with 
successful of anemia therapy.20 The 
smaller Hb-Var value, anemia 
management is close to optimal. In this 
study, high levels of Hb-Var were still 
found, most likely related to provision of 
less optimal anemia therapy. Hb-Var can 
be influenced by many factors, not only 
condition of anemia itself along with the 
treatment of anemia, other comorbidities 
such as infections and bleeding 
complications, HD and hospitalization.21,22 
Blood samples procedure can also affect 
measured Hb levels, both taken before 
and after the HD procedure. In this study, 
examination of Hb levels was carried out 
after the HD procedure in accordance with 
the local hospital policy, thus causing the 
status to underestimate the anemia profile 
due to the ultrafiltration process.23 
Median of LVIDd subjects in this 
study were 50 mm, with mean EF is 63%. 
More than 50% of subjects gave LV 
geometrical feature in form of concentric 
hypertrophy, the remainder was eccentric 
hypertrophy and little with normal 
geometry. Combination of pressure-
volume overload in CKD undergoing 
routine HD will cause a progressive 
increase in myocardium, so addition of left 
ventricle mass index (LVMI) is more 
visible than the addition of relative wall 
thickness (RWT).5 If mechanism of volume 
overload is more dominant, then feature of 
eccentric hypertrophy will be more visible. 
Combination of pressure-volume overload 
is a complex pathophysiological process, 
so that changes in LV geometry can vary 
with the characteristics of asymmetric 
hypertrophy and LV distortion.2  
Hemodialysis pattern in Indonesia 
usually uses the rules 2 times a week with 
a duration of 4 hours, due to local 
insurance policies. This pattern is below 
the standard HD conventional pattern. 
This may be a factor that contributes to 
volume overload, thus increasing number 
of CKD patients undergoing routine HD 
with eccentric hypertrophy profiles. 
Most CKD patients undergoing 
routine HD get antiremodeling therapy 
inACE-I or ARB, sometimes combined 
with CCB dihydropiridin type.This 
combination is useful for reducing LV 
maladaptivity due to excessive 
remodeling, by reducing blood pressure 
which plays a role in the pressure 
overload mechanism.24 Use of ACE-I 
and/or ARB is also known to have a mass 
regression effect of LV and interstitial 
collagen deposits, and the effect will 
increase when combined with CCB.25 The 
use of β-blockers in the subjects in this 
study is still small, which may be caused 
by non-optimal prescribing. Class-β-
blocker drugs are known to inhibit LV 
remodeling through sympathetic nervous 
system suppression, which is a 
modulation of LV remodeling process.26 
Combination of the use of ACE-I and β-
blockers is also known to reduce hospital 
admission in CKD patients.4 
Hypothesis testing shows that Hb-
Var does not affect LV dilation, soanalysis 
of confounding variables is needed to find 
risk factors for VKi dilation. The first Hb-
Var study states high Hb-Var is associated 
with mortality,8 but the Hb-Var study after 
this stated that Hb-Var was not associated 
with mortality. This is due to relative 
repetitive ischemic theory occurs due to 
high Hb-Var which is covered by many 
comorbidities in CKD patients undergoing 
routine HD, one of which is the degree of 
anemia, which has a much greater effect 
on increasing mortality.21,27,28 Subsequent 
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research tried to determine the effect of 
Hb-Var on the heart which is a specific 
organ affected by relative repetitive 
ischemia due to changes in Hb levels 
using LVMI parameters.29 The result is an 
increase in LVMI in 1 year in the group 
with baseline anemia. Increased LVMI can 
also be caused by CKD progression, 
especially combination of volume-pressure 
overload processes caused by various 
comorbidities and CKD complications, 
especially those undergoing routine HD. 
LVMI is also not a specific parameter of 
LV remodeling due to ischemic processes 
compared to LV diameter. 
Multivariate tests of risk factors for 
LV dilation show there are no variables 
that influence independently of LV dilation. 
This may be due to several variables not 
included in risk factor analysis. Most 
common cause of LV dilation in CKD 
populations undergoing routine HD is 
volume overload, and remainder including 
ischemic heart disease both coronary and 
non-coronary etiology, organic heart valve 
disorders, dilated, hypertrophic or 
arrhythmia-induced cardiomyopathy.5,30 
Risk factors related to volume overload 
that were not analyzed in this study were 
Kt/V because of difficulties in medical 
recordsdocumentation. The theory of HD-
induced ischemia is difficult to interpret as 
a measurable variable. There are no 
quantitative methods of measuring uremic 
toxins such as p-cresol and indoxyl 
sulfate. Identification of imaging degree of 
ischemia in heart muscle is only based on 
the examination of TTE that has high 
subjectivity and cannot detect severity of 
myocardial lesions, while examination of 
coronary angiography, nuclear, and 
cardiac magnetic resonance is not 
routinely performed in CKD patients 
undergoing routine HD.31 Some of factors 
mentioned above, which affect volume 
status of body fluids and ischemia that 
play a role in the LV remodeling process, 
which in this study were not included as 
confounding dilated LV. 
 
Limitation 
Limitations of this study are 
number of variables play a role in 
pathophysiology that affect process of 
ischemia and volume overload in CKD 
undergoing routine HD, but in this study 
no analysis was carried out, causing no 
significant variables cause LV dilation in 
this study, because there is no modality 
that can measure these variables, or 
examination modality has never been 
carried out in this population. Second, 
comorbid variables of hypertension and 
DM, as well as the variables of drug use 
did not include duration of diagnosis and 
duration of treatment due to limitations in 
data collection. 
 
CONCLUSION 
CKD patients undergoing routine 
HD with high Hb-Var profiles do not have 
a higher risk of LV dilation than patients 
with low Hb-Var profiles. 
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